Who is the culprit? A toxic epidermal necrolysis case in a patient treated with rituximab plus polatuzumab

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):e782-e783. doi: 10.1111/jdv.18261. Epub 2022 Jun 7.

Authors

C Zengarini^{1

2}, C Misciali^{1

2}, S Robuffo^{1

2}, B M Piraccini^{1

2}, A Pileri^{1

2}

Affiliations

¹ Dermatology Unit, IRCCS of Azienda Ospedaliero-Universitaria di Bologna, via Massarenti 9, Bologna, Italy.
² Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.

PMID: 35607916
DOI: 10.1111/jdv.18261

No abstract available

Publication types

Letter

MeSH terms

Humans
Rituximab / adverse effects
Stevens-Johnson Syndrome* / drug therapy
Stevens-Johnson Syndrome* / etiology

Substances

Rituximab